// App-Quantinova.ai

8564 : Updated results of phase 1b study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).

Researchers

Presenter

  • Anne C. Chiang

Principal Investigators

  • Charles M. Rudin

  • Alexander I. Spira

  • Robert M. Jotte

  • Shirish M. Gadgeel

  • Alain C. Mita

  • Lowell L. Hart

  • William Larry Gluck

  • Stephen V. Liu

  • Ann M. Kapoun

  • Lu Xu

  • Dawn Hill

  • Lei Zhou

  • Jakob Dupont

  • David R. Spigel

Medical Centers

  • Yale Cancer Center, New Haven, CT

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Virginia Cancer Specialists Research Institute, and Oncology Research, Fairfax, VA

  • Rocky Mountain Cancer Center, Denver, CO

  • Karmanos Cancer Institute, Detroit, MI

  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, Los Angeles, CA

  • Florida Cancer Specialists, Fort Myers, FL

  • Hem and Onc Assoc, Greenville, SC

  • Georgetown University, Washington, DC

  • OncoMed Pharmaceuticals Inc., Redwood City, CA

  • OncoMed Pharmaceuticals Inc., Redwood City, CA

  • Sarah Cannon Research Institute, Nashville, TN

Locations

  • United States

Companies

  • OncoMed Pharmaceutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Carboplatin

  • Tarextumab

  • Etoposide

  • Etoposide phosphate

  • Cisplatin

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • I

Study Id's

  • NCT01859741

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved